Cargando…
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005515/ https://www.ncbi.nlm.nih.gov/pubmed/29912950 http://dx.doi.org/10.1371/journal.pone.0199264 |
_version_ | 1783332696638881792 |
---|---|
author | Dompe, Nicholas Klijn, Christiaan Watson, Sara A. Leng, Katherine Port, Jenna Cuellar, Trinna Watanabe, Colin Haley, Benjamin Neve, Richard Evangelista, Marie Stokoe, David |
author_facet | Dompe, Nicholas Klijn, Christiaan Watson, Sara A. Leng, Katherine Port, Jenna Cuellar, Trinna Watanabe, Colin Haley, Benjamin Neve, Richard Evangelista, Marie Stokoe, David |
author_sort | Dompe, Nicholas |
collection | PubMed |
description | Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective clinically. We therefore implemented a CRISPR screening approach to identify novel agents to sensitize KRAS mutant NSCLC cells to MEK inhibitor treatment. This approach identified multiple components of the canonical RAS/MAPK pathway consistent with previous studies. In addition, we identified MAPK7 as a novel, strong hit and validated this finding using multiple orthogonal approaches including knockdown and pharmacological inhibition. We show that MAPK7 inhibition attenuates the re-activation of MAPK signaling occurring following long-term MEK inhibition, thereby illustrating that MAPK7 mediates pathway reactivation in the face of MEK inhibition. Finally, genetic knockdown of MAPK7 combined with the MEK inhibitor cobimetinib in a mutant KRAS NSCLC xenograft model to mediate improved tumor growth inhibition. These data highlight that MAPK7 represents a promising target for combination treatment with MEK inhibition in KRAS mutant NSCLC. |
format | Online Article Text |
id | pubmed-6005515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-60055152018-06-25 A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC Dompe, Nicholas Klijn, Christiaan Watson, Sara A. Leng, Katherine Port, Jenna Cuellar, Trinna Watanabe, Colin Haley, Benjamin Neve, Richard Evangelista, Marie Stokoe, David PLoS One Research Article Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective clinically. We therefore implemented a CRISPR screening approach to identify novel agents to sensitize KRAS mutant NSCLC cells to MEK inhibitor treatment. This approach identified multiple components of the canonical RAS/MAPK pathway consistent with previous studies. In addition, we identified MAPK7 as a novel, strong hit and validated this finding using multiple orthogonal approaches including knockdown and pharmacological inhibition. We show that MAPK7 inhibition attenuates the re-activation of MAPK signaling occurring following long-term MEK inhibition, thereby illustrating that MAPK7 mediates pathway reactivation in the face of MEK inhibition. Finally, genetic knockdown of MAPK7 combined with the MEK inhibitor cobimetinib in a mutant KRAS NSCLC xenograft model to mediate improved tumor growth inhibition. These data highlight that MAPK7 represents a promising target for combination treatment with MEK inhibition in KRAS mutant NSCLC. Public Library of Science 2018-06-18 /pmc/articles/PMC6005515/ /pubmed/29912950 http://dx.doi.org/10.1371/journal.pone.0199264 Text en © 2018 Dompe et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Dompe, Nicholas Klijn, Christiaan Watson, Sara A. Leng, Katherine Port, Jenna Cuellar, Trinna Watanabe, Colin Haley, Benjamin Neve, Richard Evangelista, Marie Stokoe, David A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC |
title | A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC |
title_full | A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC |
title_fullStr | A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC |
title_full_unstemmed | A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC |
title_short | A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC |
title_sort | crispr screen identifies mapk7 as a target for combination with mek inhibition in kras mutant nsclc |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005515/ https://www.ncbi.nlm.nih.gov/pubmed/29912950 http://dx.doi.org/10.1371/journal.pone.0199264 |
work_keys_str_mv | AT dompenicholas acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT klijnchristiaan acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT watsonsaraa acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT lengkatherine acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT portjenna acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT cuellartrinna acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT watanabecolin acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT haleybenjamin acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT neverichard acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT evangelistamarie acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT stokoedavid acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT dompenicholas crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT klijnchristiaan crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT watsonsaraa crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT lengkatherine crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT portjenna crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT cuellartrinna crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT watanabecolin crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT haleybenjamin crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT neverichard crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT evangelistamarie crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT stokoedavid crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc |